{"id":408442,"date":"2021-01-05T08:03:45","date_gmt":"2021-01-05T13:03:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408442"},"modified":"2021-01-05T08:03:45","modified_gmt":"2021-01-05T13:03:45","slug":"kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","title":{"rendered":"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, Jan. 5, 2021<\/span> \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.<\/a>\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO Saiid Zarrabian<\/span> will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021<\/span>.<\/p>\n

The presentation will be available for on-demand listening beginning\u00a0at 6:00 A.M. Eastern Time on Monday<\/span>, January 11, 2021, through the close of business January 14<\/span>, 2021.\u00a0 For those interested in viewing Mr. Zarrabian’s presentation, registration can be accessed here.<\/a><\/p>\n

\n ABOUT KINTARA<\/b>\n <\/p>\n

Located in San Diego, California<\/span>, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.<\/p>\n

Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs.\u00a0 The two programs are VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).<\/p>\n

VAL-083 is a\u00a0“first-in-class”,\u00a0small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). \u00a0Based on Kintara’s internal research programs and these prior\u00a0NCI-sponsored\u00a0clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of\u00a0VAL-083\u00a0in GBM.<\/p>\n

Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. \u00a0REM-001\u00a0therapy has been previously studied in four Phase 2\/3 clinical trials in patients with CMBC who had previously received chemotherapy and\/or failed radiation therapy. \u00a0With clinical efficacy to-date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the\u00a0REM-001\u00a0CMBC program to late-stage pivotal testing.\u00a0<\/p>\n

\n SAFE HARBOR STATEMENT<\/b>\n <\/p>\n

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company’s clinical trials and the GBM AGILE study.\u00a0 Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.\u00a0 The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company’s operations and clinical trials; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.\u00a0 These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended June 30, 2020<\/span>, the Company’s Quarterly Reports on Form 10-Q, and the Company’s Current Reports on Form 8-K.<\/p>\n

\n CONTACTS:
<\/b>
\n Investors:
<\/b>CORE IR
516-222-2560
ir@coreir.com<\/a><\/p>\n

\n Media:
<\/b>
\n Jules Abraham<\/span>
\n
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com<\/a><\/p>\n

\n

\n
\n \"Kintara
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/kintara-therapeutics-to-present-at-the-hc-wainwright-bioconnect-2021-virtual-conference-301200805.html<\/a><\/p>\n

SOURCE Kintara Therapeutics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, Jan. 5, 2021 \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO Saiid Zarrabian will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning\u00a0at 6:00 A.M. Eastern Time on Monday, January 11, 2021, through the close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Zarrabian’s presentation, registration can be accessed here. ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase … <\/p>\n

Continue reading “Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408442","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Jan. 5, 2021 \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO Saiid Zarrabian will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning\u00a0at 6:00 A.M. Eastern Time on Monday, January 11, 2021, through the close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Zarrabian’s presentation, registration can be accessed here. ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase … Continue reading "Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference\",\"datePublished\":\"2021-01-05T13:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"wordCount\":579,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"name\":\"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-01-05T13:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1231728\\\/Kintara_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Jan. 5, 2021 \/PRNewswire\/ —\u00a0Kintara Therapeutics, Inc.\u00a0(Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO Saiid Zarrabian will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning\u00a0at 6:00 A.M. Eastern Time on Monday, January 11, 2021, through the close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Zarrabian’s presentation, registration can be accessed here. ABOUT KINTARA Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase … Continue reading \"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:45+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference","datePublished":"2021-01-05T13:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"wordCount":579,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","name":"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","datePublished":"2021-01-05T13:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1231728\/Kintara_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kintara-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408442"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}